Results 51 to 60 of about 1,629 (148)

A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer

Case Reports in Hematology, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy that arises from plasmacytoid dendritic cells.
Jiankun Tong, Sergei Aksenov, Beth M. Siegel, Lihong Wei, William H. Rodgers   +4 more
doaj   +1 more source

Adverse Effects of Low Serum HDL‐C Levels on Prognosis and Tumor Immune Microenvironment in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Disorders of lipid metabolism contribute to the occurrence and progression of hematological malignancies, including chronic lymp hocytic leukemia (CLL). The objective of this study was to investigate the association between serum lipid levels and prognosis in patients with CLL.
Weiran Lv, Shutong Liu, Jiangtao Song, Zhijian Liang, Huaze Liao, Qianqian Huang, Ziang Zhu, Zhoupei Mo, Yun Wang, Yang Liang   +9 more
wiley   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: Report of two pediatric cases

Indian Journal of Pathology and Microbiology, 2015
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare subtype of acute leukemia that typically follows a highly aggressive clinical course in adults, whereas experience in children with this disease is very limited.
Preeti Ashok Dharmani, Neha Manish Mittal, P G Subramanian, Komal Galani, Yajamanam Badrinath, Pratibha Amare, Sumeet Gujral   +6 more
doaj   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

Incidence of Hodgkin and Non‐Hodgkin Lymphomas: Comparison of the Military and General Population

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Background Lymphoma risk varies by demographics, environmental/occupational exposures, and medical care between active‐duty service members (ADSM) and the general US population (GUSP). This study compared age‐adjusted incidence rates and trends of Hodgkin lymphoma (HL) and non‐Hodgkin lymphoma (NHL) between these groups.
Kimberly R. Robins, Julie A. Bytnar, Christin B. DeStefano, Craig D. Shriver, Kangmin Zhu   +4 more
wiley   +1 more source

Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment

British Journal of Haematology, Volume 208, Issue 4, Page 1339-1346, April 2026.
Summary Chemotherapy‐induced neutropenia, monitored by peripheral blood absolute neutrophil count (ANC), increases the risk of bloodstream infections (BSIs). However, ANC may not reflect the total neutrophil population, as it omits neutrophils at extravascular sites.
Johanna Vævest Nymann Eriksen, Silvia de Pietri, Mathias Rathe, Henrik Hasle, Christian Enevold, Claus H. Nielsen, Kjeld Schmigelow, Claus Moser, Klaus Müller, Sarah Weischendorff   +9 more
wiley   +1 more source

Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide‐Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Background Cyclophosphamide (CY) is associated with potentially fatal cardiotoxicity, yet no electrocardiographic indices have been established for early detection of CY‐induced cardiomyopathy. This study aimed to determine whether corrected QT interval (QTc) prolongation can predict early onset of CY‐related cardiac dysfunction in pediatric ...
Junpei Kawamura, Kentaro Ueno, Takuro Nishikawa, Yoshihiro Takahashi, Koji Nakae, Yasuhiro Okamoto   +5 more
wiley   +1 more source

Adult TWIST2‐high B‐ALL confirms metabolic association but reveals molecular heterogeneity

HemaSphere, Volume 10, Issue 6, June 2026.
Wencke Walter, Veronika Ecker, Wolfgang Kern, Anna Stengel   +3 more
wiley   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

Haematologica, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective therapy. In order to identify genetic alterations useful for a new treatment design, we used whole-exome sequencing
Maria Rosaria Sapienza, Francesco Abate, Federica Melle, Stefania Orecchioni, Fabio Fuligni, Maryam Etebari, Valentina Tabanelli, Maria Antonella Laginestra, Alessandro Pileri, Giovanna Motta, Maura Rossi, Claudio Agostinelli, Elena Sabattini, Nicola Pimpinelli, Mauro Truni, Brunangelo Falini, Lorenzo Cerroni, Giovanna Talarico, Rossana Piccioni, Stefano Amente, Valentina Indio, Giuseppe Tarantino, Francesco Brundu, Marco Paulli, Emilio Berti, Fabio Facchetti, Gaetano Ivan Dellino, Francesco Bertolini, Claudio Tripodo, Raul Rabadan, Stefano A. Pileri   +30 more
doaj   +1 more source

A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry

Case Reports in Hematology, 2017
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with aggressive clinical course and poor prognosis. Diagnosis is based on detection of CD4+ CD56+, CD123high, TCL-1+, and blood dendritic cell antigen-2/CD303+ blasts ...
Martina Pennisi, Clara Cesana, Micol Giulia Cittone, Laura Bandiera, Barbara Scarpati, Valentina Mancini, Silvia Soriani, Silvio Veronese, Mauro Truini, Silvano Rossini, Roberto Cairoli   +10 more
doaj   +1 more source